Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

@article{Choueiri2010RiskOA,
  title={Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.},
  author={Toni K Choueiri and F{\'a}bio Augusto Barros Schutz and Youjin Je and Jonathan E Rosenberg and Joaquim Bellmunt},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 13},
  pages={
          2280-5
        }
}
PURPOSE Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) used in a vast range of cancers. Arterial thromboembolic events (ATE) have been described with these agents, although the overall risk remains unclear. We did a systematic review and meta-analysis to determine the incidence and the relative risk (RR) associated with the use of sunitinib and sorafenib. PATIENTS AND METHODS PubMed databases were searched for articles… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 164 CITATIONS, ESTIMATED 43% COVERAGE

Manual of Cardio-oncology

  • Springer International Publishing
  • 2017
VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis

  • Cancer Chemotherapy and Pharmacology
  • 2017
VIEW 3 EXCERPTS
CITES METHODS & RESULTS
HIGHLY INFLUENCED

Novel agents in renal carcinoma: a reality check.

  • Therapeutic advances in medical oncology
  • 2012
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2010
2019

CITATION STATISTICS

  • 9 Highly Influenced Citations

  • Averaged 12 Citations per year from 2017 through 2019